MTNB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTNB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.
Matinas BioPharma Holdings's adjusted book value per share for the three months ended in Mar. 2024 was $0.067. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.18 for the trailing ten years ended in Mar. 2024.
During the past 12 months, Matinas BioPharma Holdings's average Cyclically Adjusted Book Growth Rate was -10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.
As of today (2024-05-16), Matinas BioPharma Holdings's current stock price is $0.173. Matinas BioPharma Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.18. Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio of today is 0.96.
During the past 11 years, the highest Cyclically Adjusted PB Ratio of Matinas BioPharma Holdings was 3.05. The lowest was 0.65. And the median was 1.38.
The historical data trend for Matinas BioPharma Holdings's Cyclically Adjusted Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Book per Share | Get a 7-Day Free Trial | 0.20 | 0.20 | 0.20 | 0.19 | 0.18 |
For the Biotechnology subindustry, Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.
What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?
Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.
We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Matinas BioPharma Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.067 | / | 131.7762 | * | 131.7762 | |
= | 0.067 |
Current CPI (Mar. 2024) = 131.7762.
Matinas BioPharma Holdings Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 0.202 | 100.560 | 0.265 |
201409 | 0.148 | 100.428 | 0.194 |
201412 | 0.069 | 99.070 | 0.092 |
201503 | 0.137 | 99.621 | 0.181 |
201506 | 0.151 | 100.684 | 0.198 |
201509 | 0.122 | 100.392 | 0.160 |
201512 | 0.106 | 99.792 | 0.140 |
201603 | 0.073 | 100.470 | 0.096 |
201606 | 0.052 | 101.688 | 0.067 |
201609 | 0.046 | 101.861 | 0.060 |
201612 | 0.018 | 101.863 | 0.023 |
201703 | 0.141 | 102.862 | 0.181 |
201706 | 0.102 | 103.349 | 0.130 |
201709 | 0.076 | 104.136 | 0.096 |
201712 | 0.053 | 104.011 | 0.067 |
201803 | 0.030 | 105.290 | 0.038 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | -0.014 | 106.507 | -0.017 |
201812 | 0.056 | 105.998 | 0.070 |
201903 | 0.233 | 107.251 | 0.286 |
201906 | 0.214 | 108.070 | 0.261 |
201909 | 0.209 | 108.329 | 0.254 |
201912 | 0.178 | 108.420 | 0.216 |
202003 | 0.373 | 108.902 | 0.451 |
202006 | 0.346 | 108.767 | 0.419 |
202009 | 0.323 | 109.815 | 0.388 |
202012 | 0.299 | 109.897 | 0.359 |
202103 | 0.308 | 111.754 | 0.363 |
202106 | 0.293 | 114.631 | 0.337 |
202109 | 0.269 | 115.734 | 0.306 |
202112 | 0.243 | 117.630 | 0.272 |
202203 | 0.220 | 121.301 | 0.239 |
202206 | 0.198 | 125.017 | 0.209 |
202209 | 0.178 | 125.227 | 0.187 |
202212 | 0.169 | 125.222 | 0.178 |
202303 | 0.150 | 127.348 | 0.155 |
202306 | 0.128 | 128.729 | 0.131 |
202309 | 0.107 | 129.860 | 0.109 |
202312 | 0.089 | 129.419 | 0.091 |
202403 | 0.067 | 131.776 | 0.067 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.
For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Matinas BioPharma Holdings's Cyclically Adjusted PB Ratio of today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 0.173 | / | 0.18 | |
= | 0.96 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 11 years, the highest Cyclically Adjusted PB Ratio of Matinas BioPharma Holdings was 3.05. The lowest was 0.65. And the median was 1.38.
Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.
Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Liu Hui | officer: Chief Technology Officer | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921 |
Thomas Hoover | officer: Chief Business Officer | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921 |
Kathryn Penkus Corzo | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921 |
Natasha Giordano | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Adam K Stern | director | STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019 |
Patrick G Lepore | director | 17-17 ROUTE 208 N, FAIRLAWN NJ 07410 |
Jerome D Jabbour | director, officer: Chief Executive Officer | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921 |
Keith A Kucinski | officer: Chief Financial Officer | C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Herbert J Conrad | director | C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8 |
Ferguson James J. Iii | officer: Chief Medical Officer | C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Theresa Matkovits | officer: Chief Development Officer | C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545 |
Gary Gaglione | officer: Chief Financial Officer | C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Matthew Wikler | director | VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Raphael J Mannino | officer: Chief Scientific Officer | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
From GuruFocus
By [email protected] insider • 11-26-2019
By PRNewswire PRNewswire • 09-27-2021
By PRNewswire PRNewswire • 09-22-2021
By PRNewswire PRNewswire • 09-30-2021
By PRNewswire PRNewswire • 12-07-2020
By GuruFocus Research • 11-08-2023
By PRNewswire PRNewswire • 09-23-2021
By PRNewswire PRNewswire • 12-30-2020